Skip to main content
Fig. 7 | Journal of Experimental & Clinical Cancer Research

Fig. 7

From: ER-α36 mediates cisplatin resistance in breast cancer cells through EGFR/HER-2/ERK signaling pathway

Fig. 7

Up-regulation of ER-α36 attenuates cisplatin sensitivity in a nude mouse xenograft model. a, b The nude mice bearing MCF-7/V cell-derived and MCF-7/ER-α36 cell-derived subcutaneous tumors were treated intraperitoneally with or without cisplatin (DDP) for 2 weeks, the xenograft tumors were harvested (a) and the tumor volume was calculated as described in Methods (b). c ER-α36 protein levels in each group were evaluated by western blot. d MCF-7/V tumors treated with or without cisplatin were analyzed for ER-α36 protein levels using western blotting. *P < 0.05, ** P < 0.01, ***P < 0.001

Back to article page